Table 1 Patients clinical characteristics

Gender (male N %)

21 (95%)

49 (86%)

Age (years)

62.7 ± 8.2

63.4 ± 8.4

BMI (kg/m²)

27.8 ± 5.1

28.5 ± 4.3

HbA1C (%)

5.6 ± 0.3

7.8 ± 1.4**

Glucose( mg/dL)

101.9 ± 27.7

168.1 ± 54.1**

EF (%)

 Normal

11 (50%)

22 (39%)

 Mild

8(36%)

26 (46%)

 Moderate

3 (14%)

7 (20%)

 Severe

0

1 (2%)

LV Hypertrophy (N%)

7 (31%)

24 (42%)

S/P MI

13 (54.1%)

41 (54.2%)

Total Cholesterol (mg/dL)

136.3 ± 49.1

140.9 ± 41.7

HDL (mg/dL)

37 ± 7.9

37.8 ± 11.7

Triglycerides (mg/dL)

107.4 ± 33

169.8 ± 122*

LDL cholesterol (mg/dL)

76.5 ± 39.0

70.7 ± 31.0

Creatinine (mg/dL)

0.9 ± 0.3

0.39 ± 0.3

Hypertension (N %)

18 (75%)

48 (85%)

RAS blockers (N %)

 ACEi

15(68%)

25 (44%)

 ARBs

3 (13%)

14 (25%)

 Spironolacton

1 (4.5%)

2(3%)

 Non

3(13%)

15 (26%)

Anti-diabetic Tx (N %)

 Insulin

0

21 (37%)

 Met

0

39 (68%)

 SGLT2i

0

9 (16%)

 GLP1

0

5 (9%)

 DPP4

0

5 (9%)

 Sulfanilurea

0

13 (22%)